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Loss of intracellular compartmentalization of potassium is a biochemical feature of Alzheimer’s disease indicating a loss
of membrane integrity and mitochondrial dysfunction. We examined potassium and rubidium (a biological proxy for
potassium) in brain tissue, blood fractions and cerebrospinal fluid from Alzheimer’s disease and healthy control subjects
to investigate the diagnostic potential of these two metal ions. We found that both potassium and rubidium levels were
significantly decreased across all intracellular compartments in the Alzheimer’s disease brain. Serum from over 1000
participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL), showed minor changes
according to disease state. Potassium and rubidium levels in erythrocytes and cerebrospinal fluid were not significantly
different according to disease state, and rubidium was slightly decreased in Alzheimer’s disease patients compared to
healthy controls. Our data provides evidence that contrasts the hypothesized disruption of the blood-brain barrier in
Alzheimer’s disease, with the systemic decrease in cortical potassium and rubidium levels suggesting influx of ions from
the blood is minimal and that the observed changes are more likely indicative of an internal energy crisis within the brain.
These findings may be the basis for potential diagnostic imaging studies using radioactive potassium and rubidium tracers.Introduction
Mitochondrial dysfunction and impaired energy metabo-
lism are features that immediately precede neuronal loss
in Alzheimer’s disease (AD) [1]. Oxidative stress arising
from neurotoxic β-amyloid (Aβ) accumulation and
oligomerization causes a loss in membrane integrity in
the synapse [2], which is heavily dependent on sufficient
ATP production to regulate ion transport in and out of
the cell [3]. Oligomeric Aβ species adversely affect cellular
function through a range of hypothesized mechanisms, a
number of which directly compromise both energy
production and membrane potential [4, 5].
Impaired energy production related to AD pathology has
been of research interest. Positron emission tomography* Correspondence: blaine.roberts@florey.edu.au
ˆDeceased
1The Florey Institute of Neuroscience, The University of Melbourne, Parkville,
VIC, Australia
2Cooperative Research Centre for Mental Health, Parkville, VIC, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze(PET) has identified a metabolic decrease in glucose
consumption in the AD brain [6], which is indicative of
reduced neural activity [7] and direct impairment of
Na+/K+-ATPase-regulated intramembrane ion trans-
port [8]. Thus, there is potential that markers of
modified K+ handling may be indicative of AD, and
could be a useful preclinical marker of increased
AD risk.
As a group 1 alkali metal, rubidium (Rb+) has simi-
lar biochemical characteristics to K+ [9]. Though it
has no known biological function, Rb+ is present in
almost all biological systems due to its ability to
readily exchange with K+ [10]. Assessment of Rb+ is a
useful proxy for K+, so much so that turnover of
radioactive 86Rb+ has been successfully used as a
measure of basal metabolic rate [11]. Rubidium assays
are also less prone to environmental contamination,
and the ion is present in biological matrices at
concentrations well suited to contemporary analytical
techniques [12].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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numerous conflicting reports of either changes to [13, 14]
or stability of [15–17] Rb and K levels in AD, most likely
due to low statistical power. Here, we used post mortem
brain tissue from the Victorian Brain Bank Network
along with blood samples from the Australian Imaging,
Biomarkers and Lifestyle Flagship Study of Ageing [18],
which is one of the world’s largest longitudinal studies
of AD, to investigate changes in the regulation of K+
and Rb+ from a system-wide perspective. We aimed to




All brain tissues were obtained from the Victorian Brain
Bank Network, and all experiments were approved by
the University of Melbourne health sciences, human
ethics subcommittee (ID1136882). Tissue was collected
at autopsy, frozen at −80 °C, then thawed to −20 °C and
sectioned into 1 cm slices. From these, c.a. 5 g samples
of frontal cortex were collected and 0.5 g aliquots of
grey matter dissected and stored at −80 °C until analysis.
Neurological control tissues were defined as free from
AD lesions with the number of plaque and tangles were
well below the cut-off values for the neuropathological
diagnosis of AD (NIA Reagan criteria). No other neuro-
logical disease was present.
Preparation of tissue homogenate fractions
Sample preparation steps for tissue samples were adapted
our previously reported methods [19, 20]. Aliquots
(0.1–0.3 g) of dissected grey matter from the frontal
cortex were thawed on ice and homogenized in single-
use BioMasher (Omni International) vials. After centri-
fugation at 100,000 g a 1:4 tissue-to-buffer (w/v) ratio
of Tris buffered saline (TBS; 50 mM Tris, pH 8.0, 150 mM
NaCl) with EDTA-free protease inhibitors (Roche) was
added to each homogenate. Samples were transferred to
ultracentrifuge vials, spun at 100,000 g for 30 min at 4 °C,
and then had the supernatant removed (the ‘soluble’ frac-
tion). The remaining pellet was isolated and resuspended
with 1:4 (w/v) 100 mM NaCO3 (pH 11.0), then centrifuged
again at 100,000 g for 30 min at 4 °C to retrieve the
‘vesicular’ fraction. Remaining material was then subjected
to extraction of membrane-bound proteins and metals (the
‘membrane’ fraction) by addition of 1:4 (w/v) 7 M urea,
2 M thiourea, 4 % 3-[(3-cholamidopropyl) dimethylammo-
nio]-1-propanesulfonate (CHAPS) and 30 mM Bicine
(pH 8.5) and further centrifugation at 100,000 g for 30 min
at 4 °C. Any remaining ‘insoluble’ material was then
digested in 70 % formic acid for c.a. 18 h before centrifuga-
tion as performed for all other extractions. No material
remained at the conclusion of fractionation experiments.Preparation of blood samples
Protocols for the preparation of serum and erythrocytes
was followed according to our previously reported method
[21]. Whole blood was drawn from AIBL subjects after
overnight fasting. For serum collection, blood was drawn
into serum-gel 7.5 mL tubes (Sarstedt) and left standing at
room temperature for 20 min before centrifugation at
1800 g for 15 min. Serum was split into 250 μL aliquots
and stored in liquid nitrogen until analysis. After thawing,
serum samples were spun briefly at 1800 g and diluted
1:10 in 1 % HNO3 for analysis. Platelets were recovered by
centrifuging a plasma fraction (collected from whole blood
in a lithium-heparin tube) at 800 g for 15 min and re-
moving the plasma supernatant.
Erythrocytes were collected from blood samples taken
after an overnight fast into standard lithium-heparin
7.5 mL tubes (Sarstedt). Samples were spun at 3200 g to
remove plasma and platelets, leaving erythrocytes that
were washed three times in 0.9 % (w/v) NaCl. Erythro-
cytes were distributed by inverting the tube and then
centrifuged at 650 g for 10 min, after which the super-
natant was removed and samples were spun again at
1500 g for 10 min at room temperature. Erythrocytes
were then resuspended in 6 mL of 0.1 M PBS and stored
in liquid nitrogen until analysis. A 50 μL of thawed eryth-
rocytes were transferred to 1.5 mL polypropylene tubes
and digested in equal volumes of 65 % HNO3 and ≥30 %
H2O2 on a hotplate at 80 °C. After cooling, samples were
diluted 1:20 with 1 % HNO3. Platelets were prepared for
analysis using the same digestion procedure as described
for erythrocytes.
Preparation of CSF samples
Cerebrospinal fluid was collected using the gravity drip
method described by Rembach et al. [22]. Patients
underwent a lumbar puncture procedure following an
overnight fast, and up to 8 mL of CSF was collected
directly into a 15 mL polypropylene tube. Samples were
centrifuged at 2000 g at 4 °C and then divided into
300 μL aliquots and stored on liquid nitrogen. After
thawing, 100 μL aliquots were diluted 1:10 with 1 %
HNO3 for analysis.
Rubidium and potassium analysis
All metal analyses were performed on an Agilent 7700×
Series inductively coupled plasma-mass spectrometer
(ICP-MS) using a Teflon MiraMist nebulizer (Burgener
Research Inc.) and Scott-type double-pass spray chamber
(Glass Expansion). Helium was used as a collision gas to
remove potential polyatomic interferences. The instru-
ment was calibrated using multi-element standards
(Accustandard, ICP-MS-2-1, ICP-MS-3-1, ICP-MS-4-1;
total of 44 elements) containing K and Rb at 0, 5, 10, 50,
100 and 500 μg L−1 with 89Y introduced online
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85Rb were monitored. Seronorm™ L1 and L2 (Sero)
were reconstituted in 1:20, 1 % HNO3 prior to
analysis for use as quality control standards.
Statistical analysis
All statistical testing was performed in GraphPad Prism
v6.0 h using unpaired t-tests, one-way ANOVA and
Pearson correlation analysis as appropriate. Significance
was defined as p < 0.05 after Bonferroni post-hoc testing.
Results
K and Rb levels are consistently decreased in fractionated
brain homogenates
We analyzed post mortem AD and healthy control (HC)
frontal cortical tissue (n = 30 per group, matched for age
and sex; see Table 1 for demographics) by subjecting
homogenates of frontal cortex to a stepwise fractionation
process that extracted material into ‘soluble’, vesicular-
peripheral membrane (‘vesicular’), membrane-bound
(‘membrane’) and ‘insoluble’ classifications [19]. These
solutions were then assayed for total K and Rb content
using inductively coupled plasma-mass spectrometry
(ICP-MS; see Materials and Methods). In AD frontal
cortex significant decreases in both K and Rb levels were
apparent (Fig. 1a-b). The degree of change increased in
magnitude from the ‘soluble’ to ‘insoluble’ fractions.
As expected, a high degree of correlation between
tissue K and Rb levels were observed regardless of
diagnosis (r = 0.862 (HC); r = 0.738 (AD); both p <
0.001; Fig. 1c-d). However, the slope measured by
linear regression was significantly decreased in the AD
brains (63.7 % of HC; F = 5.41, p < 0.05). A receiver
operating characteristic (ROC) curve of both K and Rb
levels in the total homogenate (which showed the largest
difference between clinical classifications) found that Rb
performed better at predicting AD, with an area under the
curve of 0.815 versus 0.754 for K (both p < 0.01; Fig. 1e-f).
Serum levels of K and Rb are altered in
Alzheimer’s disease
To investigate whether the observed changes in K and






Age (years) 76.8 (7.6) 78.3 (9.2) 0.56
Females (%) 33.3 26.7 0.59
% APOE ε4 carriers 13.3 75.8 <0.001
Post mortem interval
(hours)
38.4 (14.3) 33.9 (21.9) 0.38
Mean (standard deviation); p-value calculated using a two-tailed
Student’s t-testperiphery, we examined serum K and Rb concentrations
in the entire baseline AIBL cohort, including the mildly
cognitively impaired group (ntotal = 1077; nHC = 778;
nMCI = 128; nAD = 171; Table 2; see Ellis et al. [18] for
cohort full demographics). Significant differences were
observed for both analytes between HC and AD groups,
but these shifts did not reflect the magnitude or direc-
tion of those observed in the brain. There was a 2.6 %
increase in serum K levels in the AD subjects (Fig. 2a),
with a small (5.4 %) decrease in serum Rb (Fig. 2b).
There was a highly significant (p < 0.001) decrease in the
ratio of Rb to K in the AD group (Fig. 2c), though ROC
analysis revealed changes in all three measures were less
robust (though still statistically significant) indicators of
AD than total Rb and K in brain homogenates (AUCK =
0.569; AUCRb = 0.575; AUCRb:K = 0.6115; Additional file 1:
Figure S1). K and Rb levels correlated in both groups,
although again to a much lesser extent than in brain
homogenates, and the slopes of both lines did not differ
(F = 0.21; p = 0.65; Fig. 2d).
Rb levels are decreased in platelets, but not erythrocytes
or CSF
We analyzed a subset of AD and HC erythrocytes for Rb
and K concentrations (n = 40 per classification) and
found no significant difference between groups (p = 0.62;
Fig. 2e, f ). K levels in a subset of HC, AD and MCI
platelets (nHC = 50, nAD = 41, nMCI = 7; Table 3) were not
different between groups (Fig. 3a). Rb levels in AD plate-
lets were significantly decreased compared to the HC
group (one-way ANOVA; p < 0.05; Fig. 3b; Table 4). This
decrease in Rb levels in platelets showed limited diag-
nostic potential when examined using an ROC curve
(Additional file 1: Figure S2). In cerebrospinal fluid
(CSF; nHC = 36, nAD = 9, nMCI = 7; Table 5) K and Rb
levels were unaltered according to clinical classification
(Fig. 3c, d).
Discussion
Our results expand upon a previous smaller study that
reported decreased Rb levels in the AD brain [23]; we
found here that Rb levels are decreased in interstitial/
cytosolic, vesicular, membrane-bound and otherwise
insoluble fractions, and that these changes correlate with
and reflect decreased K levels in the same isolates. Both
K and Rb levels have been shown to be decreased in
homogenates from a range of brain regions that show
progressive neurodegeneration in AD [24]. We found no
compelling evidence that K and Rb levels external to the
brain (i.e., blood products and CSF) have diagnostic
potential in AD research.
Our data suggests that the observed effects of
impaired alkali metal metabolism in the AD brain, such
as altered Na+/K+-ATPase activity manifest as a decrease in
Fig. 1 a, b K and Rb levels in fractionated brain homogenates were consistently decreased in AD brains (n= 30 per group; one-way ANOVA; ** p < 0.01;
*** p< 0.001; percentage decrease in AD group compared to healthy controls shown). Error bars represent the standard error of the mean. c Both metals
showed significant correlation regardless of clinical classification (p< 0.001), though the slope of the line of best fit was significantly decreased in the AD
group (p < 0.05). d, e Both metals performed well at predicting AD via ROC curve analysis, with Rb slightly superior performance
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to a specific fraction. We found that the decrease was of a
higher magnitude (c.a. 50 %) within cellular membranes
(i.e., the ‘membrane’ and ‘insoluble’ fractions). It is unclear
as to whether a reduction in K (and, by nature of its ability
to exchange, Rb) is a cause or effect of the disease process,
though a number of genes associated with K transport
and flux have been identified as showing decreasedTable 2 Subject demographics of the baseline AIBL cohort










Age (years) 70.6 (7) 76.2 (7.6) 78.8 (8.6) <0.001
Females (%) 57.6 56.3 62.0 0.34
% APOE
ε4 carriers
27.2 49.2 62.4 <0.001
CDR SOB 0.0 (0.1) 1.2 (0.8) 5.8 (2.9) <0.001
MMSE 28.9 (1.2) 26.2 (2.7) 18.9 (5.3) <0.001
CDR SOB is the Clinical Dementia Rating Scale Sum of Boxes score used to
stage dementia. MMSE is the mini-mental state examination questionnaire
score. p-value calculated using a one-way ANOVA or chi-squared test
for percentagestranscription levels in the AD brain [25]. In vitro studies of
mixed cortical cultures have shown that Aβ induces K+
efflux via enhancing the delayed rectifier K+ current
IK [26], potentially through the formation of transient
ion channels in bilayer membranes [27].
Importantly, this disruption of cellular metabolism in
AD likely commences well before the appearance of
histopathological features and the onset of clinical symp-
toms. Genome-wide transcriptomic analysis of AD brains
identified as many as 70 % of genes encoding subunits of
the mitochondrial electron transport chain were expressed
at lower levels in regions of the brain most affected by AD
when compared to controls [28]. Neural network analysis
of ‘seed genes’ (the principal genes from which regulatory
pathways are grown [29]) identified those encoding the
master energy regulator AMP-activated protein kinase as
being dysregulated in AD [30].
The effects of impaired energy metabolism appear to
primarily result in a loss of membrane integrity through
its negative impact on active transport mechanisms that
regulate resting membrane potential. As the major
consumer of energy in the cell—maintaining resting
potential and action potentials accounts for 20–50 % of
energy use in neurons in the cortex [31]—the action of
Fig. 2 K levels were significantly increased in AD serum (a; one-way ANOVA; * p< 0.05), whilst Rb levels were conversely decreased in AD
(b; * p< 0.05); the latter mirroring our observation in brain homogenates. The ratio of Rb to K was significantly (*** p< 0.001) decreased in AD (c), though
Rb and K levels were less well correlated in serum (d). In a subset (n= 30 per group) of erythrocytes from HC and AD groups, there was no significance
difference in metal concentration (e, f). Boxes depict 25th and 75th percentiles and mean; error bars represent minimum to maximum values
Roberts et al. Acta Neuropathologica Communications  (2016) 4:119 Page 5 of 8Na+/K+-ATPase is easily compromised by energy
deficits. In the AD brain, Na+/K+-ATPase activity is
depressed [32], with a reduction in α3 subunit mRNA
observed, a process that occurs prior to the formation
of Aβ plaques and is rapidly accelerated in the disease






Age (years) 82.0 (8.0) 82.0 (8.0) 0.97
Females (%) 52.5 50.0 0.96
% APOE ε4 carriers 37.5 60.0 0.05
p-value calculated using a two-tailed Student’s t-testcrisis is inexorably linked to the molecular basis of the
disease.
These findings may have diagnostic potential in the
clinical setting. Rubidium-82 has been extensively used
in positron emission tomography (PET) as a diagnostic
marker for brain tumors [34], with increased uptake of the
Rb-82 tracer indicative of a loss of blood-brain barrier
(BBB) integrity. Permeability of the BBB is thought to be a
feature of both normal aging and AD [35], though both in-
creased serum K concentrations in AD and a failure to
identify a change in CSF K or Rb levels tends to suggest
that BBB permeability is not directly responsible for the
decrease in akali metal levels in the AD brain. Further, a
recent study using animal models of AD, including the
lipopolysaccharide (LPS) model of induced inflammation,










Age (years) 73.8 (6.3) 71.6 (4.8) 80.8 (7.8) <0.001
Females (%) 60 14.3 75.6 <0.01
% APOE ε4
carriers
20 28.6 75.6 <0.001
p-value calculated using a one-way ANOVA or chi-squared test for percentages










Age (years) 71.8 (5.6) 68.3 (4.5) 71.3 (7.1) 0.40
Females (%) 58.0 57.1 33.3 0.41
% APOE ε4
carriers
19 0 44.4 0.20
p-value calculated using a one-way ANOVA or chi squared test for percentages
Fig. 3 K and Rb levels in platelets and CSF. a, b In platelets no
significant changes were observed for K, though Rb was significantly
decreased (p < 0.01; one-way ANOVA) in AD subjects compared to
controls. c, d K and Rb levels in CSF remained unchanged. Boxes depict
25th and 75th percentiles and mean; error bars represent minimum to
maximum values
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APOE knockout and APOE4 knock-in mice showed no
evidence of BBB permeability compared to both wild type
and a positive multiple sclerosis model control using
multiple assays, including Rb-86 radiotracer experiments
[36], questioning the long-held belief that BBB disruption is
characteristic of AD.
Receiver-operating characteristic curve analysis of brain
Rb levels (Fig. 2f) shows that changes in levels of this
metal is a strong predictor of AD, therefore Rubidium-82/
86 PET imaging could be used to identify early-stage AD.
Considering that alkali metal homeostasis is disrupted via
decreased Na+/K+-ATPase activity prior to Aβ plaque for-
mation, this approach may have greater preclinical value
than the contemporary method employing Pittsburgh
compound-B to assess brain amyloid burden by PET [37].
However, if the BBB integrity is maintained in AD,
delivery of the imaging agent presents a challenge to use
as a preclinical diagnostic tool. An intact BBB still demon-
strates a small degree (2.1 %) of Rb uptake, though this is
ten-fold less than typically observed in cases of brain tu-
mors and associated BBB disruption [38]. Hyperosmolar
BBB disruption via injection of 25 % mannitol to the
carotid artery has been shown to induce a temporary
window for 82Rb loading into the baboon brain [39],
though the safety of this approach in humans remains
untested beyond patients with pre-existing brain tumors.
A non-invasive scanning ultrasound approach to tempor-
arily open the BBB in the APP23 transgenic AD mouse
model was shown to be effective in clearing accumulated
Aβ [40], and a number of clinical trials testing the safety
and efficacy of this approach, predominantly for drug
delivery, are currently ongoing [41]. Development of a
suitable BBB-permeable vehicle that releases Rb into the
brain is an intriguing line of enquiry.
An alternative means to monitor brain Rb levels
without the need to deliver an exogenous tracer uses the
paramagnetic properties of the naturally occurring 87Rb
radioisotope, which accounts for approximately 28 % of
Rb in the natural environment. T1 and T2 relaxation
times are well suited to magnetic resonance imaging
using specialized coils, and this approach has been used
to quantitatively assess K (using 87Rb as a proxy) in the
brains of ischemic rats [42, 43]. This approach uses
Roberts et al. Acta Neuropathologica Communications  (2016) 4:119 Page 7 of 8chronic Rb loading via drinking water in the weeks
preceding MRI scanning, which could be employed in a
diagnostic workflow for AD, though the use of high field
strength (e.g., 7 T) MRI systems may have the capacity
to assess endogenous 87Rb with sufficient sensitivity.
Conclusions
We have shown that Rb and K levels are consistently de-
creased across all cellular components in the AD frontal
cortex, and altered to a lesser extent in the periphery. As
Rb is readily exchangeable with K, we hypothesize that
this decrease is indicative of dysfunctional Na+/K+-ATPase
activity, a pathological feature of AD that is representative
of an internal energy crisis and precedes the formation of
proteinaceous inclusions and neuron loss in the disease.
Rubidium levels in the brain performed well in predicating
AD, and may represent a new avenue of early diagnosis
using existing in vivo imaging techniques, including PET
and MRI.
Additional file
Additional file 1: ROC analysis of Rb & K levels in plasma (Figure S1)
and platelets (Figure S2). (DOCX 1297 kb)
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